Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Shkreli Comments on EpiPen Price Hike, Mylan CEO Has 671% Salary Increase

By Meg Snyder | August 24, 2016

As the media is stirring up over the price hike of Mylan’s EpiPen—from $100 for a two-pen set in 2007 to more than $600 in 2016—a number of voices are speaking out on the issue, Martin Shkreli being one of them.

Most well-known for his endorsed price hike of Turing’s antiparasitic drug Daraprim (used to treat toxoplasmosis and prevent infections such as malaria and HIV) from $13.50 to $750 per tablet, Shkreli is making his opinions about EpiPen’s price tag known—even as Congress demands a response from Mylan as to why the price for the EpiPen has skyrocketed.

Shkreli defended Mylan to CBS News on Tuesday in an interview. 

“Mylan is the good guy. They had one product, and they finally started making a little bit of money and everyone is going crazy over it,” said Shkreli. “It’s $300 a pack. $300. My iPhone is $700. . . . It’s $300 and 90 percent of Americans are insured.”

Shkreli is currently under indictment for securities fraud.

After Mylan’s competitor took a similar product off the market, Mylan now essentially holds a monopoly.

In a statement, Mylan said they “are committed to working with customers and payers to find solutions to meet the needs of the patients and families we serve.” 

Furthermore, Mylan’s CEO, Heather Bresch, is expected to reap some serious benefits from EpiPen’s profits.

According to Forbes:

But that 400% increase in wholesale price for EpiPen looks meager compared to the whopping 671% salary increase company CEO Heather Bresch is reported to have enjoyed in that same time period. . . . 

According to NBC News, Bresch earned $2,453,456 in 2007, the year of the EpiPen acquisition. In 2015, Bresch’s total compensation was $18,931,068. It may have even been slightly more than that and appears to have been even more than that in 2014.

Lead image photo credit: Intropin.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50